A possible beneficial effect of Bacteroides on faecal lipopolysaccharide activity and cardiovascular diseases.
Aged
Animals
Bacteroides
/ genetics
Cardiovascular Diseases
/ metabolism
Case-Control Studies
Feces
/ chemistry
Female
Gastrointestinal Microbiome
Humans
Lipopolysaccharides
/ metabolism
Male
Mice
Mice, Inbred C57BL
Middle Aged
Probiotics
RAW 264.7 Cells
RNA, Ribosomal, 16S
/ genetics
Retrospective Studies
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 08 2020
03 08 2020
Historique:
received:
12
09
2019
accepted:
15
07
2020
entrez:
5
8
2020
pubmed:
5
8
2020
medline:
7
5
2021
Statut:
epublish
Résumé
Faecal lipopolysaccharides (LPS) have attracted attention as potent elements to explain a correlation between the gut microbiota and cardiovascular disease (CVD) progression. However, the underlying mechanism of how specific gut bacteria contribute to faecal LPS levels remains unclear. We retrospectively analysed the data of 92 patients and found that the abundance of the genus Bacteroides was significantly and negatively correlated with faecal LPS levels. The controls showed a higher abundance of Bacteroides than that in the patients with CVD. The endotoxin units of the Bacteroides LPS, as determined by the limulus amoebocyte lysate (LAL) tests, were drastically lower than those of the Escherichia coli LPS; similarly, the Bacteroides LPS induced relatively low levels of pro-inflammatory cytokine production and did not induce sepsis in mice. Fermenting patient faecal samples in a single-batch fermentation system with Bacteroides probiotics led to a significant increase in the Bacteroides abundance, suggesting that the human gut microbiota could be manipulated toward decreasing the faecal LPS levels. In the clinical perspective, Bacteroides decrease faecal LPS levels because of their reduced LAL activity; therefore, increasing Bacteroides abundance might serve as a novel therapeutic approach to prevent CVD via reducing faecal LPS levels and suppressing immune responses.
Identifiants
pubmed: 32747669
doi: 10.1038/s41598-020-69983-z
pii: 10.1038/s41598-020-69983-z
pmc: PMC7398928
doi:
Substances chimiques
Lipopolysaccharides
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13009Références
Yoshida, N. et al. Bacteroides vulgatus and Bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis. Circulation 138, 2486–2498. https://doi.org/10.1161/CIRCULATIONAHA.118.033714 (2018).
doi: 10.1161/CIRCULATIONAHA.118.033714
pubmed: 30571343
Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031. https://doi.org/10.1038/nature05414 (2006).
doi: 10.1038/nature05414
Xavier, R. J. & Podolsky, D. K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427–434. https://doi.org/10.1038/nature06005 (2007).
doi: 10.1038/nature06005
pubmed: 17653185
Maeda, Y. et al. Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. Arthritis Rheumatol. 68, 2646–2661. https://doi.org/10.1002/art.39783 (2016).
doi: 10.1002/art.39783
pubmed: 27333153
Pedersen, H. K. et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535, 376–381. https://doi.org/10.1038/nature18646 (2016).
doi: 10.1038/nature18646
pubmed: 27409811
Schiattarella, G. G. et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose–response meta-analysis. Eur. Heart J. 38, 2948–2956. https://doi.org/10.1093/eurheartj/ehx342 (2017).
doi: 10.1093/eurheartj/ehx342
pubmed: 29020409
The Human Microbiome Project. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214. https://doi.org/10.1038/nature11234 (2012).
doi: 10.1038/nature11234
Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55–60. https://doi.org/10.1038/nature11450 (2012).
doi: 10.1038/nature11450
pubmed: 23023125
Jie, Z. et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat. Commun. 8, 845. https://doi.org/10.1038/s41467-017-00900-1 (2017).
doi: 10.1038/s41467-017-00900-1
pubmed: 29018189
pmcid: 5635030
Liu, R. et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat. Med. 23, 859–868. https://doi.org/10.1038/nm.4358 (2017).
doi: 10.1038/nm.4358
pubmed: 28628112
Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446–450. https://doi.org/10.1038/nature12721 (2013).
doi: 10.1038/nature12721
pubmed: 24226770
Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63. https://doi.org/10.1038/nature09922 (2011).
doi: 10.1038/nature09922
pubmed: 21475195
pmcid: 3086762
Vatanen, T. et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell 165, 842–853. https://doi.org/10.1016/j.cell.2016.04.007 (2016).
doi: 10.1016/j.cell.2016.04.007
pubmed: 27133167
pmcid: 4950857
d’Hennezel, E., Abubucker, S., Murphy, L. O. & Cullen, T. W. Total lipopolysaccharide from the human gut microbiome silences toll-like receptor signaling. mSystems 2, e0004617. https://doi.org/10.1128/mSystems.00046-17 (2017).
doi: 10.1128/mSystems.00046-17
Wiedermann, C. J. et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J. Am. Coll. Cardiol. 34, 1975–1981. https://doi.org/10.1016/s0735-1097(99)00448-9 (1999).
doi: 10.1016/s0735-1097(99)00448-9
pubmed: 10588212
Anker, S. D. & von Haehling, S. Inflammatory mediators in chronic heart failure: an overview. Heart 90, 464–470. https://doi.org/10.1136/hrt.2002.007005 (2004).
doi: 10.1136/hrt.2002.007005
pubmed: 15020532
pmcid: 1768165
Pastori, D. et al. Gut-derived serum lipopolysaccharide is associated with enhanced risk of major adverse cardiovascular events in atrial fibrillation: effect of adherence to Mediterranean diet. J. Am. Heart Assoc. 6, 5784. https://doi.org/10.1161/JAHA.117.005784 (2017).
doi: 10.1161/JAHA.117.005784
Kim, K. A., Jeong, J. J., Yoo, S. Y. & Kim, D. H. Gut microbiota lipopolysaccharide accelerates inflamm-aging in mice. BMC Microbiol. 16, 9–9. https://doi.org/10.1186/s12866-016-0625-7 (2016).
doi: 10.1186/s12866-016-0625-7
pubmed: 26772806
pmcid: 4715324
Zhou, S. Y. et al. FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. J. Clin. Invest. 128, 267–280. https://doi.org/10.1172/JCI92390 (2018).
doi: 10.1172/JCI92390
pubmed: 29202473
Jang, S. E. et al. Gastrointestinal inflammation by gut microbiota disturbance induces memory impairment in mice. Mucosal Immunol. 11, 369–379. https://doi.org/10.1038/mi.2017.49 (2018).
doi: 10.1038/mi.2017.49
pubmed: 28612842
Neff, C. P. et al. Fecal microbiota composition drives immune activation in HIV-infected individuals. EBiomedicine 30, 192–202. https://doi.org/10.1016/j.ebiom.2018.03.024 (2018).
doi: 10.1016/j.ebiom.2018.03.024
pubmed: 29650491
pmcid: 5952409
Fabbiano, S. et al. Functional gut microbiota remodeling contributes to the caloric restriction-induced metabolic improvements. Cell Metab. 28, 907-921.e7. https://doi.org/10.1016/j.cmet.2018.08.005 (2018).
doi: 10.1016/j.cmet.2018.08.005
pubmed: 6288182
pmcid: 6288182
Mancuso, G. et al. Bacteroides fragilis-derived lipopolysaccharide Produces Cell Activation and Lethal Toxicity via toll-like receptor 4. Infect. Immun. 73, 5620–5627. https://doi.org/10.1128/IAI.73.9.5620-5627.2005 (2005).
doi: 10.1128/IAI.73.9.5620-5627.2005
pubmed: 16113279
pmcid: 1231095
Munford, R. S. Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant?. Infect. Immun. 76, 454–465. https://doi.org/10.1128/IAI.00939-07 (2008).
doi: 10.1128/IAI.00939-07
pubmed: 18086818
Gronbach, K. et al. Endotoxicity of lipopolysaccharide as a determinant of T-cell−mediated colitis induction in mice. Gastroenterology 146, 765–775. https://doi.org/10.1053/j.gastro.2013.11.033 (2014).
doi: 10.1053/j.gastro.2013.11.033
pubmed: 24269927
Poxton, I. R. & Edmond, D. M. Biological activity of Bacteroides lipopolysaccharide - reappraisal. Clin. Infect. Dis. 20(Suppl 2), S149–S153. https://doi.org/10.1093/clinids/20.supplement_2.s149 (1995).
doi: 10.1093/clinids/20.supplement_2.s149
pubmed: 7548538
Takagi, R. et al. A single-batch fermentation system to simulate human colonic microbiota for high-throughput evaluation of prebiotics. PLoS ONE 11, e0160533. https://doi.org/10.1371/journal.pone.0160533 (2016).
doi: 10.1371/journal.pone.0160533
pubmed: 27483470
pmcid: 4970706
Sasaki, D. et al. Low amounts of dietary fibre increase in vitro production of short-chain fatty acids without changing human colonic microbiota structure. Sci. Rep. 8, 435. https://doi.org/10.1038/s41598-017-18877-8 (2018).
doi: 10.1038/s41598-017-18877-8
pubmed: 29323180
pmcid: 5765155
Yoshida, N. et al. Effect of resistant starch on the gut microbiota and its metabolites in patients with coronary artery disease. J. Atheroscler. Thromb. 26, 705–719. https://doi.org/10.5551/jat.47415 (2019).
doi: 10.5551/jat.47415
pubmed: 30587666
pmcid: 6711844
Hayashi, T. et al. Gut microbiome and plasma microbiome-related metabolites in patients with decompensated and compensated heart failure. Circ. J. 83, 182–192. https://doi.org/10.1253/circj.CJ-18-0468 (2018).
doi: 10.1253/circj.CJ-18-0468
pubmed: 30487369
Senni, M. et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 98, 2282–2289. https://doi.org/10.1161/01.cir.98.21.2282 (1998).
doi: 10.1161/01.cir.98.21.2282
pubmed: 9826315
Mancia, G. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 34, 2159–2219. https://doi.org/10.1093/eurheartj/eht151 (2013).
doi: 10.1093/eurheartj/eht151
pubmed: 23771844
Furet, J. P. et al. Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR. FEMS Microbiol. Ecol. 68, 351–362. https://doi.org/10.1111/j.1574-6941.2009.00671.x (2009).
doi: 10.1111/j.1574-6941.2009.00671.x
pubmed: 19302550
Mori, H. et al. Design and experimental application of a novel non-degenerate universal primer set that amplifies prokaryotic 16S rRNA genes with a low possibility to amplify eukaryotic rRNA genes. DNA Res. 21, 217–227. https://doi.org/10.1093/dnares/dst052 (2014).
doi: 10.1093/dnares/dst052
pubmed: 24277737
Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120. https://doi.org/10.1093/bioinformatics/btu170 (2014).
doi: 10.1093/bioinformatics/btu170
pubmed: 24695404
pmcid: 4103590
Yarza, P. et al. The all-species living tree project: a 16S rRNA-based phylogenetic tree of all sequenced type strains. Syst. Appl. Microbiol. 31, 241–250. https://doi.org/10.1016/j.syapm.2008.07.001 (2008).
doi: 10.1016/j.syapm.2008.07.001
pubmed: 18692976
Yamashita, T. et al. Resistance to endotoxin shock in transgenic mice overexpressing endothelial nitric oxide synthase. Circulation 101, 931–937. https://doi.org/10.1161/01.cir.101.8.931 (2000).
doi: 10.1161/01.cir.101.8.931
pubmed: 10694534
Rezania, S. et al. Extraction, purification and characterization of lipopolysaccharide from Escherichia coli and Salmonella typhi. Avicenna J. Med. Biotechnol. 3, 3–9 (2011).
pubmed: 23407691
pmcid: 3558174
Wexler, A. G. & Goodman, A. L. An insider’s perspective: Bacteroides as a window into the microbiome. Nat. Microbiol. 2, 17026. https://doi.org/10.1038/nmicrobiol.2017.26 (2017).
doi: 10.1038/nmicrobiol.2017.26
pubmed: 28440278
pmcid: 5679392